文献速递胰腺与胆道疾病

辛伐他汀预防复发性胰腺炎:三盲随机临床试验(SIMBA试验)

Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial).
PubMed 文献 · Gut · 2026-05-12

SIMBA试验为三盲随机对照优效性研究,纳入85例既往12个月内至少2次复发性急性胰腺炎或慢性胰腺炎急性发作的患者,比较辛伐他汀与安慰剂1年。意向性分析显示复发率46.2%对44.4%(OR 1.07,95%CI 0.43-2.66,p=0.88),无显著差异;辛伐他汀组新发糖尿病更常见(4对0例,p=0.04)。

要点

  • 辛伐他汀未降低复发性胰腺炎1年复发率(46.2%对44.4%,p=0.88)。
  • 辛伐他汀组新发糖尿病4例,安慰剂组0例(p=0.04)。
  • 试验因招募缓慢提前终止,结果可能把握度不足。

核心结论

  • 辛伐他汀与安慰剂相比未显著降低复发性胰腺炎或慢性胰腺炎急性发作的复发率,但试验提前终止可能导致把握度不足。

研究设计与样本

  • 23个中心开展的三盲、随机、对照、优效性试验,计划样本量144例,因招募缓慢进行期中分析,实际纳入85例(女性42.1%)。
  • 纳入标准为既往12个月内至少2次复发性急性胰腺炎或慢性胰腺炎急性发作,随机接受辛伐他汀或安慰剂1年。
  • 主要终点为胰腺炎复发。

主要发现

  • 意向性分析中复发率辛伐他汀组46.2%对安慰剂组44.4%,OR 1.07(95%CI 0.43-2.66),p=0.88。
  • 符合方案分析中复发率辛伐他汀组35.5%对安慰剂组41.9%,OR 0.76(95%CI 0.27-2.12),p=0.60。
  • 新发糖尿病辛伐他汀组4例对安慰剂组0例,OR无法计算,p=0.04。

关键数值与推荐

  • 主要终点复发率差异无统计学意义(OR 1.07,95%CI 0.43-2.66,p=0.88)。
  • 符合方案分析复发率差异无统计学意义(OR 0.76,95%CI 0.27-2.12,p=0.60)。
  • 新发糖尿病组间差异有统计学意义(4对0例,p=0.04)。

临床怎么用

  • 当前证据不支持辛伐他汀用于预防复发性胰腺炎或慢性胰腺炎急性发作。
  • 使用他汀类药物的此类患者需关注新发糖尿病风险,但需进一步研究验证。

局限性

  • 试验因招募缓慢提前终止,实际样本量85例低于计划144例,结果可能把握度不足。
  • 期中分析可能影响结果的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent acute pancreatitis (RAP) or acute-on-chronic flares in chronic pancreatitis (CP) have limited preventive options beyond addressing the underlying aetiology. Statins, due to their anti-inflammatory properties, have been proposed as a potential prophylactic treatment. OBJECTIVE: We aimed to evaluate whether simvastatin could reduce the recurrence of pancreatitis. DESIGN: At 23 centres, we conducted a triple-blind, randomised, controlled, superiority trial enrolling patients with at least two episodes of RAP or CP flares in the previous 12 months. Participants were randomly assigned to receive simvastatin or placebo for 1 year. The primary endpoint was the recurrence of pancreatitis. The target sample size was 144 patients; however, an interim analysis was planned in the event of slow recruitment. RESULTS: A total of 85 patients (42.1% women) were included in the interim analysis. In the intention-to-treat analysis, no significant differences were observed regarding recurrence: 46.2% simvastatin versus 44.4% placebo; OR 1.07, 95% CI 0.43 to 2.66; p=0.88, or time to recurrence. No statistically significant differences were observed in recurrence in per-protocol analysis (35.5% simvastatin vs 41.9% placebo; OR 0.76, 95% CI 0.27 to 2.12; p=0.60). Development of diabetes mellitus was more frequent in the simvastatin group (4 vs 0 patients; OR not calculable, p=0.04). CONCLUSION: This trial, evaluating simvastatin versus placebo for the prevention of pancreatitis, did not demonstrate a reduction in recurrence rate, although results might be underpowered due to early termination. The relationship between statins in these patients and new-onset diabetes requires further investigation. TRIAL REGISTRATION NUMBER: NCT04021498.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A, et al. Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial). Gut. 2026. PMID: 41482454. doi:10.1136/gutjnl-2025-337154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。